Authors: Mishchenko T.S.1, Mishchenko V.M.1, Kufterina N.S.2
1 State Institution «Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
2 Kharkiv National Medical University, Kharkiv, Ukraine
Summary
An open-label clinical study on the efficacy and tolerability of the drug Muscomed, manufactured by World Medicine company, has been carried out in patients with muscular tonic syndromes. Muscomed contains thiocolchicoside as an active substance, a semisynthetic muscle relaxant, extracted from natural glycoside colchicoside. It has a muscle relaxant effect, reduces or eliminates muscle spasms, caused by the influence from the central nervous system.
Objective of the study
To evaluate the efficacy and tolerability of the drug Muscomed, manufactured by World Medicine company, in patients with muscular tonic syndromes.
Research tasks
To study the therapeutic efficacy of Muscomed, its impact on the severity of the muscular tonic syndrome; to examine the tolerability and possible side effects of the drug being studied; to compare the therapeutic effect of Muscomed and the drug Tolperil-Zdoroviie in the treatment of muscular tonic syndrome.
Material of the study
60 individuals of both sexes aged 18 to 65 years with muscular tonic syndromes, who underwent inpatient and/or outpatient treatment in the department of cerebrovascular pathology of the State Institution «Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine». Depending on the therapy, all patients were divided into 2 equal groups: 1 — 30 people receiving Muscomed 2 ml 2 times a day i.m. for 5 days on a background of generally accepted standard therapy; 2 — 30 individuals, who received Tolperil-Zdoroviie 1 ml 2 times a day on a background of generally accepted standard therapy.
Methods of the study
General clinical one, clinical-neurological and neuropsychological research using scales (Schober test, Roland-Morris questionnaire, visual analogue scale, Hospital Anxiety and Depression Scale, McGill Pain questionnaire, EuroQoL 5D quality of life questionnaire), instrumental (X-ray, magnetic resonance imaging), biochemical, clinical laboratory, statistical ones.
Results and discussion
Results of this study allow us to conclude that the drug Muscomed has a quite significant therapeutic effect on muscular tonic syndromes, easy to use, as well as leads to improved physical well-being, increased ability to work and the quality of life of patients.
Key words: muscular tonic syndromes, vertebrogenic pain syndromes, Muscomed, treatment, neuromuscular blocking agents.